Drug developers take fresh aim at 'guided-missile' cancer drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
SVB Leerink Starts GlaxoSmithKline (GSK:LN) (GSK) at Outperform
January 6, 2020 7:58 AM ESTSVB Leerink initiates coverage on GlaxoSmithKline (GSK:LN) (NYSE: GSK) with a Outperform rating and a price target of GBP21.00.
... More